Company Research Report: Neuronano AB

Company Overview

Name: Neuronano AB

Mission of the Company: To invent, patent, develop, and commercialize a new generation of innovative electrodes for implantation in the brain and spinal cord to improve quality of life for individuals with neurological illnesses.

Founded: Neuronano AB was established with a collaboration between the Neuronano Research Center at Lund University, led by Dr. Jens Schouenborg.

Key People: Dr. Jens Schouenborg (Principal Inventor), Maria Bech (VP Business Development), Dr. Jörgen Hager (CTO), Niclas Lindqvist (Scientist).

Headquarters: Pirgatan 13, 374 35 Karlshamn, Sweden.

Research & Development Location: Medicon Village, SE-223 81 Lund, Sweden.

Number of Employees: No information is available.

Revenue: No information is available.

What is the Company Known For: Neuronano AB is recognized for its innovative solutions in advanced neurotechnology, specifically offering novel Deep Brain Stimulation (DBS) technologies to alleviate symptoms for neurological conditions like Parkinson’s disease.

Products

Products Offered

1. Deep Brain Stimulation (DBS) Electrodes

Description: The DBS electrodes are designed to stimulate nerve cells in the brain, adapting to brain movements without irritating or damaging tissue, enabling stable contact with the nerve cells.

Key Features:

Groundbreaking, thinner, and flexible electrode design.

High biocompatibility reducing encapsulation and neuron loss.

Includes ultra-flexible and biodegradable carriers to minimize surgical damage and enable precise electrode implantation.

2. Pro Active Tissue Stabilizer

Description: Utilizes algorithms to predict body movements to adjust the Patient Positioning Platform, compensating for phase lag between compensatory movement and actual movement.

Key Features:

Algorithm-based predictive movement compensation.

3. 3D Project Recording

Description: Offers solutions for long-term stability in neural interfaces to record individual neurons in the brain.

Key Features:

Improved stability for neuron recording.

Recent Developments

New Products Launched: New design concepts for DBS devices have been generated focusing on user and patient needs, supported by Vinnova funding.

New Features Added: Development of the biodegradable carrier further refined to ensure minimal impact on neuronal tissue.

New Partnerships: Initiated collaboration with Århus University for advanced neurotechnology projects.

Notable Personnel Additions:

Maria Bech joined as VP Business Development, bringing extensive experience in clinical testing and business development.

Dr. Jörgen Hager appointed as CTO with a robust background in product development in the medical device industry.

Research Advances: Jens Schouenborg and team developed high-definition brain stimulation (HDBS) technology using microelectrode clusters, allowing personalized stimulation treatments without noticeable side effects.

Patents and Innovations: Ongoing expansion of patent portfolio that includes biodegradable implantation solutions and precise electrode cluster usages.

Highlighted News and Achievements

May 2024: Scientist Niclas Lindqvist focused on the development and optimization of the DBS probe gelatin component.

February 2023: Research centered around solving persistent intolerable pain, a major socioeconomic issue, led by Matilde Forni at Neuronano Research Center.

July 2022: Dr. Jens Schouenborg participated in a panel discussion about decoding the senses, showcasing expertise and innovation in neurotechnology.

This detailed company report on Neuronano AB highlights the company's innovations and contributions to neuroscience and neurotechnology, focusing on improving patient outcomes with advanced neurostimulative solutions. Future updates and ongoing research are expected to further solidify Neuronano AB's position as a leader in the med tech industry.